JP2015530358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530358A5 JP2015530358A5 JP2015521549A JP2015521549A JP2015530358A5 JP 2015530358 A5 JP2015530358 A5 JP 2015530358A5 JP 2015521549 A JP2015521549 A JP 2015521549A JP 2015521549 A JP2015521549 A JP 2015521549A JP 2015530358 A5 JP2015530358 A5 JP 2015530358A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- active ingredient
- conjugate according
- composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 239000004480 active ingredient Substances 0.000 claims 32
- 210000004027 cell Anatomy 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 239000002872 contrast media Substances 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 8
- 210000003470 mitochondria Anatomy 0.000 claims 6
- 230000002438 mitochondrial effect Effects 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000035699 permeability Effects 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000000805 cytoplasm Anatomy 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- -1 antibody Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- GPRSOIDYHMXAGW-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopentanecarboxylic acid iron Chemical group [CH-]1[CH-][CH-][C-]([CH-]1)C(=O)O.[CH-]1C=CC=C1.[Fe] GPRSOIDYHMXAGW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120075444 | 2012-07-11 | ||
| KR10-2012-0075444 | 2012-07-11 | ||
| KR20120104173 | 2012-09-19 | ||
| KR10-2012-0104173 | 2012-09-19 | ||
| KR10-2012-0109207 | 2012-09-28 | ||
| KR20120109207 | 2012-09-28 | ||
| KR20130017046 | 2013-02-18 | ||
| KR10-2013-0017046 | 2013-02-18 | ||
| KR20130043635 | 2013-04-19 | ||
| KR10-2013-0043635 | 2013-04-19 | ||
| PCT/KR2013/006218 WO2014010971A1 (ko) | 2012-07-11 | 2013-07-11 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530358A JP2015530358A (ja) | 2015-10-15 |
| JP2015530358A5 true JP2015530358A5 (cg-RX-API-DMAC7.html) | 2016-09-01 |
| JP6272853B2 JP6272853B2 (ja) | 2018-01-31 |
Family
ID=49916328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521549A Active JP6272853B2 (ja) | 2012-07-11 | 2013-07-11 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10967000B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2873678B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6272853B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101799904B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104822698B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2981865T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014010971A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2875826B1 (en) | 2012-05-11 | 2017-08-23 | KAEL-GemVax Co.,Ltd | Composition for preventing or treating sepsis |
| KR20150014483A (ko) | 2012-05-11 | 2015-02-06 | 주식회사 카엘젬백스 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 |
| ES2999332T3 (en) | 2012-09-19 | 2025-02-25 | Gemvax & Kael Co Ltd | Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate |
| US9631184B2 (en) | 2012-09-19 | 2017-04-25 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| ES2716870T3 (es) | 2013-04-19 | 2019-06-17 | Gemvax & Kael Co Ltd | Composición para el tratamiento y prevención de lesión isquémica |
| CN105535931A (zh) | 2013-06-07 | 2016-05-04 | 凯尔杰姆维克斯有限公司 | 在癌症免疫疗法中有用的生物标记 |
| ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
| BR112016008331B1 (pt) | 2013-10-23 | 2023-01-31 | Sang Jae Kim | Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp |
| WO2015076621A1 (ko) | 2013-11-22 | 2015-05-28 | 주식회사 카엘젬백스 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
| JP6420459B2 (ja) | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー，リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
| CN106659149B (zh) | 2014-04-30 | 2020-05-19 | 珍白斯凯尔有限公司 | 用于器官、组织或细胞移植的组合物、试剂盒和移植方法 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| EP3263122B1 (en) | 2015-02-27 | 2020-05-06 | Gemvax & Kael Co., Ltd. | Peptide for preventing hearing loss, and composition comprising same |
| ES2879641T3 (es) | 2015-05-26 | 2021-11-22 | Gemvax & Kael Co Ltd | Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen |
| WO2017003267A1 (ko) | 2015-07-02 | 2017-01-05 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| CN105018499A (zh) * | 2015-08-25 | 2015-11-04 | 武汉大学 | 一种抗乙型肝炎病毒的肽核酸及其用途 |
| EP3372613A4 (en) * | 2015-11-03 | 2019-07-10 | Gemvax & Kael Co., Ltd. | PEPTIDE WITH NERVE DAMAGE PREVENTION AND REGENERATION EFFECT AND COMPOSITION THEREOF |
| US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| CN109563131A (zh) * | 2016-04-11 | 2019-04-02 | 卡诺有限责任公司 | 手性肽 |
| CN106236695A (zh) * | 2016-06-02 | 2016-12-21 | 哈尔滨源茂达生物技术有限公司 | 一种多肽祛痘修复精华液及其制备方法 |
| JP7239987B2 (ja) | 2016-06-06 | 2023-03-15 | アスクリピウム タイワン シーオー．， エルティーディー． | 薬物送達のための抗体融合タンパク質 |
| KR101797167B1 (ko) * | 2016-11-09 | 2017-11-13 | 주식회사 바이오셀트란 | 신규의 프로테인 트랜스덕션 도메인 및 이의 용도 |
| CN107759698A (zh) * | 2017-09-18 | 2018-03-06 | 广东工业大学 | 一种egfp‑cta2‑tat融合蛋白在制备荧光探针中的应用 |
| WO2019070962A1 (en) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | BICYCLIC PEPTIDE INHIBITORS |
| WO2019084528A1 (en) * | 2017-10-27 | 2019-05-02 | Ohio State Innovation Foundation | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR ADMINISTRATION OF STAPLED PEPTIDES |
| WO2019148195A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Cyclic peptidyl inhibitors of cal-pdz binding domain |
| US11987647B2 (en) | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
| CN109553659B (zh) * | 2018-11-26 | 2022-06-21 | 上海华新生物高技术有限公司 | 一种细胞穿透肽及透皮干扰素 |
| KR102351041B1 (ko) | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| WO2020130547A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 엘알알씨24 단백질 유래 세포막 투과 도메인 |
| KR102182985B1 (ko) * | 2019-01-03 | 2020-11-26 | 주식회사 바이오이즈 | pH 의존적 막 투과성 펩타이드를 이용한 약물 운반체 및 그것과 약물의 복합체 |
| CN113950337A (zh) * | 2019-01-03 | 2022-01-18 | 金圣千 | 利用pH依赖性细胞膜穿透肽的药物载体以及所述药物载体与药物的复合体 |
| AU2020259449A1 (en) | 2019-04-17 | 2021-12-09 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of molecules |
| US20230020092A1 (en) * | 2019-12-19 | 2023-01-19 | Entrada Therapeutics, Inc. | Compositions for delivery of antisense compounds |
| CN115461358A (zh) * | 2020-07-17 | 2022-12-09 | 养生堂有限公司 | 一种细胞穿膜肽及其应用 |
| EP4198058A4 (en) * | 2020-08-13 | 2024-10-16 | Nibec Co., Ltd. | ANTIBODIES AGAINST INTRACELLULAR TUMOR-INDUCING PROTEIN OR FUSION PROTEIN OF A SINGLE-STRANDED VARIABLE FRAGMENT THEREOF AND CANCER CELL PENETRATING PEPTIDE AND USE THEREOF |
| CN114731988B (zh) * | 2022-05-23 | 2023-10-20 | 昆明市第一人民医院 | 一种hbv感染的树鼩模型构建方法及树鼩模型 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU207799B (en) | 1991-07-24 | 1993-06-28 | Beres Export Import Rt | Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis |
| US5885782A (en) * | 1994-09-13 | 1999-03-23 | Nce Pharmaceuticals, Inc. | Synthetic antibiotics |
| JP2000515523A (ja) | 1996-07-22 | 2000-11-21 | ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター | 創傷および線維性障害の治療における性ステロイド機能モジュレーターの使用 |
| US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| ATE361099T1 (de) | 1997-05-15 | 2007-05-15 | Chugai Pharmaceutical Co Ltd | Heilmittel für kachexie |
| AU748442B2 (en) | 1997-07-01 | 2002-06-06 | Cambia | Vertebrate telomerase genes and proteins and uses thereof |
| AU754278B2 (en) * | 1998-03-26 | 2002-11-07 | Kyowa Hakko Kogyo Co. Ltd. | Monoclonal antibody against human telomerase catalytic subunit |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
| US7078491B1 (en) * | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
| US6815426B2 (en) | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| JP4228700B2 (ja) | 2001-04-10 | 2009-02-25 | 日本新薬株式会社 | 慢性関節リウマチの治療剤 |
| CN100556450C (zh) | 2001-05-16 | 2009-11-04 | 耶达研究发展有限公司 | Il-18抑制剂在治疗或预防脓毒症中的应用 |
| AU2002363231A1 (en) | 2001-10-29 | 2003-05-12 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen |
| US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| JP4430403B2 (ja) | 2002-04-10 | 2010-03-10 | メルク セローノ ソシエテ アノニム | 線維化疾患の治療および／または予防のためのオステオプロテゲリンの使用 |
| KR20050020987A (ko) | 2002-06-12 | 2005-03-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법 |
| WO2005000227A2 (en) | 2003-06-06 | 2005-01-06 | Intermune, Inc. | Methods of treating tnf-mediated disorders |
| AU2004248998A1 (en) | 2003-06-25 | 2004-12-29 | Takeda Pharmaceutical Company Limited | Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity |
| KR20050040517A (ko) | 2003-10-29 | 2005-05-03 | 주식회사 오리엔트 | 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐 |
| DK1530965T3 (da) | 2003-11-11 | 2006-07-17 | Mattern Udo | Kontrolleret frigivelsesleveringssystem til nasal applikation |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| EP2374458A1 (en) | 2005-03-21 | 2011-10-12 | Vicus Therapeutics SPE 1, LLC | Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS |
| TW200803894A (en) | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
| EP1968643A2 (en) | 2005-12-16 | 2008-09-17 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids into a cell |
| EP1991560B1 (en) * | 2006-02-20 | 2018-04-04 | Ewha University-Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
| EP2044108A4 (en) | 2006-07-24 | 2010-06-30 | Forhumantech Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION |
| JP5518488B2 (ja) | 2007-01-29 | 2014-06-11 | プロセル セラピューティックス インコーポレーティッド | 巨大分子伝達ドメインならびにその同定方法および使用 |
| CA2691980C (en) | 2007-06-29 | 2022-05-10 | Correlogic Systems, Inc. | Predictive markers for ovarian cancer |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| WO2009025871A1 (en) | 2007-08-23 | 2009-02-26 | University Of Medicine And Dentistry Of Nj | Telomerase reverse transcriptase variant |
| EP2212696B1 (en) | 2007-10-25 | 2013-12-04 | Genelux Corporation | Systems and methods for viral therapy |
| GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| JP5787752B2 (ja) | 2008-06-16 | 2015-09-30 | メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ | 抗腫瘍免疫療法 |
| US8252282B2 (en) | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
| ES2334315B1 (es) | 2008-07-29 | 2011-02-28 | Universitat Pompeu Fabra | Peptidos con capacidad de penetracion celular y sus usos. |
| CA2734487A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| US20110183925A1 (en) | 2008-09-22 | 2011-07-28 | Nisshin Pharma Inc. | Anti-inflammatory peptide |
| EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| KR101169030B1 (ko) * | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
| JP5826742B2 (ja) | 2009-05-07 | 2015-12-02 | ドンコック ファーマシューティカル カンパニー リミテッド | 神経損傷及び神経疾患の予防または治療用薬学組成物 |
| EP2251028A1 (en) | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| US7928067B2 (en) | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| CA2762551C (en) * | 2009-05-20 | 2016-11-22 | Toray Industries, Inc. | Cell-penetrating peptides |
| KR20110057049A (ko) | 2009-11-23 | 2011-05-31 | 박의신 | 기능성 전립선염 치료제 |
| KR20110062943A (ko) | 2009-12-04 | 2011-06-10 | 주식회사종근당 | 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제 |
| ES2664866T3 (es) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg |
| EP3581649A1 (en) | 2010-02-16 | 2019-12-18 | Ultimovacs ASA | Polypeptides |
| FR2960542B1 (fr) | 2010-05-27 | 2012-08-17 | Esther Suzy Arlette Fellous | Peptide en tant que medicament, en particulier pour le traitement du cancer |
| KR101263212B1 (ko) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | 신규한 세포막 투과성 펩타이드 및 그의 용도 |
| WO2011150493A1 (en) | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for antimicrobials |
| KR101388372B1 (ko) | 2010-06-11 | 2014-04-23 | 한국화학연구원 | 청각보호 작용을 하는 신규 화합물 |
| KR101348284B1 (ko) * | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| KR20120121196A (ko) | 2011-04-26 | 2012-11-05 | 주식회사 글루칸 | 관절염 치료제 |
| KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
| KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
| KR101288053B1 (ko) | 2011-07-04 | 2013-07-23 | 동국대학교 산학협력단 | 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물 |
| KR101361445B1 (ko) | 2011-12-26 | 2014-02-12 | 성균관대학교산학협력단 | 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물 |
| SG11201404570WA (en) | 2012-02-10 | 2014-11-27 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| KR102041381B1 (ko) | 2012-03-12 | 2019-11-27 | 젬백스 에이에스 | 능동적인 면역치료법을 이용한 비-소세포성 폐암의 치료 |
| KR20150014483A (ko) | 2012-05-11 | 2015-02-06 | 주식회사 카엘젬백스 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 |
| EP2875826B1 (en) | 2012-05-11 | 2017-08-23 | KAEL-GemVax Co.,Ltd | Composition for preventing or treating sepsis |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| ES2999332T3 (en) | 2012-09-19 | 2025-02-25 | Gemvax & Kael Co Ltd | Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate |
| ES2802253T3 (es) | 2012-09-19 | 2021-01-18 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
| KR102038487B1 (ko) | 2012-09-19 | 2019-10-30 | 주식회사 젬백스앤카엘 | 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물 |
| US9631184B2 (en) | 2012-09-19 | 2017-04-25 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| KR20140104288A (ko) | 2013-02-20 | 2014-08-28 | 주식회사 카엘젬백스 | Tnf-알파 저해제 |
| ES3047667T3 (en) | 2013-02-22 | 2025-12-04 | Univ Leland Stanford Junior | Methods relating to telomere extension |
| ES2716870T3 (es) | 2013-04-19 | 2019-06-17 | Gemvax & Kael Co Ltd | Composición para el tratamiento y prevención de lesión isquémica |
| CN105535931A (zh) | 2013-06-07 | 2016-05-04 | 凯尔杰姆维克斯有限公司 | 在癌症免疫疗法中有用的生物标记 |
| ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
| BR112016008331B1 (pt) | 2013-10-23 | 2023-01-31 | Sang Jae Kim | Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp |
| WO2015076621A1 (ko) | 2013-11-22 | 2015-05-28 | 주식회사 카엘젬백스 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
| JP6420459B2 (ja) | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー，リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
| CN106659149B (zh) | 2014-04-30 | 2020-05-19 | 珍白斯凯尔有限公司 | 用于器官、组织或细胞移植的组合物、试剂盒和移植方法 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| EP3263122B1 (en) | 2015-02-27 | 2020-05-06 | Gemvax & Kael Co., Ltd. | Peptide for preventing hearing loss, and composition comprising same |
| EP3372613A4 (en) | 2015-11-03 | 2019-07-10 | Gemvax & Kael Co., Ltd. | PEPTIDE WITH NERVE DAMAGE PREVENTION AND REGENERATION EFFECT AND COMPOSITION THEREOF |
| KR20170054310A (ko) | 2015-11-09 | 2017-05-17 | 주식회사 젬백스앤카엘 | 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법 |
-
2013
- 2013-07-11 EP EP13816880.2A patent/EP2873678B8/en active Active
- 2013-07-11 US US14/413,732 patent/US10967000B2/en active Active
- 2013-07-11 JP JP2015521549A patent/JP6272853B2/ja active Active
- 2013-07-11 ES ES13816880T patent/ES2981865T3/es active Active
- 2013-07-11 CN CN201380044357.3A patent/CN104822698B/zh active Active
- 2013-07-11 KR KR1020157002484A patent/KR101799904B1/ko active Active
- 2013-07-11 WO PCT/KR2013/006218 patent/WO2014010971A1/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015530358A5 (cg-RX-API-DMAC7.html) | ||
| He et al. | Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer | |
| Bajracharya et al. | Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems | |
| Chen et al. | Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis | |
| JP2016500648A5 (cg-RX-API-DMAC7.html) | ||
| McCord et al. | Folate receptors’ expression in gliomas may possess potential nanoparticle-based drug delivery opportunities | |
| Guimarães et al. | Nanoparticles for immune cytokine TRAIL-based cancer therapy | |
| Nam et al. | Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides | |
| JP2015530404A5 (cg-RX-API-DMAC7.html) | ||
| Ruan et al. | Stapled RGD peptide enables glioma-targeted drug delivery by overcoming multiple barriers | |
| Kondapi | Targeting cancer with lactoferrin nanoparticles: recent advances | |
| Chittasupho et al. | Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles | |
| JP2016500513A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | Targeting cancer gene therapy with magnetic nanoparticles | |
| Kang et al. | A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma | |
| Timur et al. | The role of peptide-based therapeutics in oncotherapy | |
| US20120283316A1 (en) | Delivery of Therapeutic Agents Using Oligonucleotide-Modified Nanoparticles As Carriers | |
| Bian et al. | Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery | |
| Sorolla et al. | Peptides, proteins and nanotechnology: A promising synergy for breast cancer targeting and treatment | |
| He et al. | A novel progress of drug delivery system for organelle targeting in tumour cells | |
| Kong et al. | Progress in tumour-targeted drug delivery based on cell-penetrating peptides | |
| AU2018273958A1 (en) | PD-1 and CTLA-4 dual inhibitor peptides | |
| WO2015135597A1 (en) | Uses and methods for delivery to the nucleus | |
| Noguchi et al. | Effects of lyophilization of arginine-rich cell-penetrating peptide-modified extracellular vesicles on intracellular delivery | |
| Sawant et al. | Cancer research and therapy: Where are we today |